NK cell-mediated cytotoxicity modulation by A(2) adenosine receptor agonist in different mammalian species
Language English Country United States Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- Adenosine analogs & derivatives immunology pharmacology MeSH
- Adenosine A2 Receptor Agonists * MeSH
- Killer Cells, Natural drug effects immunology MeSH
- Cytotoxicity, Immunologic drug effects MeSH
- Rodentia MeSH
- Goats MeSH
- Rats MeSH
- Cells, Cultured MeSH
- Humans MeSH
- Mice, Inbred C57BL MeSH
- Mice MeSH
- Neoplasms immunology MeSH
- Rats, Wistar MeSH
- Swine MeSH
- Receptors, Adenosine A2 immunology MeSH
- Animals MeSH
- Check Tag
- Rats MeSH
- Humans MeSH
- Male MeSH
- Mice MeSH
- Female MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Adenosine MeSH
- Adenosine A2 Receptor Agonists * MeSH
- N-cyclopropyl adenosine-5'-carboxamide MeSH Browser
- Receptors, Adenosine A2 MeSH
Adenosines, endogenous purine nucleosides, appear in the extracellular space under metabolically stressful conditions associated with ischemia, inflammation, and cell damage. Their activity on innate immunity is prevalently inhibitory and can develop both in infectious and neoplastic diseases. During cancer development, tumor cells that release high concentrations of adenosines can impair the function of tumor-infiltrating lymphocytes and assist tumor growth by neo-angiogenesis. We evaluated the influence of A(2) adenosine receptor (A(2)AR) agonist on cytotoxic-cell response comparing human with other mammalian species (rodents, pigs, goats), both in healthy and in cancer conditions. The A(2)AR agonist developed dose-dependent inhibition of the cytotoxic activity of immune effector cells in all studied species. However, variability of the response was observed in relation to the species and the target cells that were used. Altogether, our data indicate that the A(2)AR plays a central role in adenosine-mediated inhibition of immune response to tumors.
See more in PubMed
Int J Oncol. 2008 Mar;32(3):527-35 PubMed
Lung Cancer. 2005 Feb;47(2):215-23 PubMed
Folia Microbiol (Praha). 2003;48(3):403-7 PubMed
J Appl Physiol (1985). 1994 Jan;76(1):5-13 PubMed
Biochem J. 2005 Nov 1;391(Pt 3):575-80 PubMed
Cell Signal. 2002 Feb;14(2):99-108 PubMed
Nature. 2001 Dec 20-27;414(6866):916-20 PubMed
Proc Natl Acad Sci U S A. 2006 Aug 29;103(35):13132-7 PubMed
Immunol Res. 2006;36(1-3):91-9 PubMed
J Environ Pathol Toxicol Oncol. 1994;13(1):59-61 PubMed
Annu Rev Immunol. 2004;22:657-82 PubMed
Neuropharmacology. 1997 Sep;36(9):1127-39 PubMed
Nat Rev Drug Discov. 2008 Sep;7(9):759-70 PubMed
Melanoma Res. 2003 Dec;13(6):543-8 PubMed
J Neuroimmunol. 2002 Sep;130(1-2):55-65 PubMed
Pharmacol Rev. 2001 Dec;53(4):527-52 PubMed
Biochem Pharmacol. 2003 Feb 15;65(4):493-501 PubMed
Cancer Res. 1990 Jul 15;50(14):4328-31 PubMed
Cell Immunol. 1994 Nov;159(1):85-93 PubMed
J Immunol. 2005 Oct 1;175(7):4383-91 PubMed
Cancer Res. 2006 Aug 1;66(15):7758-65 PubMed
